Listing 1 - 4 of 4 |
Sort by
|
Choose an application
This book analyses the relationships among product safety strategy and culture, concurrent engineering, new product development (NPD) processes and product safety performance. Product safety is a matter of enormous economic and societal concern, given the safety risks to consumers and the financial risks to producers. Nevertheless, a thorough conceptual understanding of the effects of NPD policies and practices is still largely missing, as several large-scale trends have made clarifying the role of product safety in its socio-economic context difficult, including: the rise of consumerism and the shift in the balance of power from manufacturers to customers and regulators; the internationalization of value chains and the fragmentation of markets worldwide; and technological change leading to a sophistication of products that rendered average consumers increasingly unaware of risk and potential accidents. This volume sets out to close the gaps among research, practice and policy, with an emphasis on advocating responsible product innovation. Through an in-depth study of the durable juvenile products industry, the authors discover important relationships, for example that top management involvement, safety-first culture and robust NPD processes are paramount in increasing product safety and decreasing product recalls in firms. On the other end of the spectrum, concurrent engineering does not automatically lead to product safety, they found no “magic bullet” through which product safety can be tied to the use of a particular tool, skill, or practice. Offering a dynamic framework for aligning the interests of multiple stakeholders, including manufacturers, regulators, and consumers, the authors provide a clearer understanding of product safety and its implications for scholars, students, policy makers, and practitioners in the areas of innovation management, product management, R&D management, and responsible research and innovation.
Business. --- Project management. --- Management. --- Industrial management. --- Quality control. --- Reliability. --- Industrial safety. --- Economic policy. --- Business and Management. --- Innovation/Technology Management. --- Project Management. --- R & D/Technology Policy. --- Quality Control, Reliability, Safety and Risk. --- Product safety. --- Product design. --- Commercial products --- New products --- Industrial design --- Consumer protection --- Products liability --- Warning labels --- Design and construction --- Safety measures --- System safety. --- Safety, System --- Safety of systems --- Systems safety --- Accidents --- Industrial safety --- Systems engineering --- Economic nationalism --- Economic planning --- National planning --- State planning --- Economics --- Planning --- National security --- Social policy --- Industrial project management --- Management --- Administration --- Industrial relations --- Organization --- Prevention --- Industrial accidents --- Industries --- Job safety --- Occupational hazards, Prevention of --- Occupational health and safety --- Occupational safety and health --- Prevention of industrial accidents --- Prevention of occupational hazards --- Safety, Industrial --- Safety engineering --- Safety of workers --- System safety --- Dependability --- Trustworthiness --- Conduct of life --- Factory management --- Industrial engineering --- Reliability (Engineering) --- Sampling (Statistics) --- Standardization --- Quality assurance --- Quality of products --- Business administration --- Business enterprises --- Business management --- Corporate management --- Corporations --- Industrial administration --- Management, Industrial --- Rationalization of industry --- Scientific management --- Business --- Industrial organization
Choose an application
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation. Health care innovation is possibly the greatest opportunity and challenge of our generation. This important book shows how pharmaceutical companies will continue to play an instrument role in making our lives better. Stefan Thomke, William Barclay Harding Professor of Business Administration, Harvard Business School Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book! Karima Boubekeur, VP Emerging Portfolio and Search & Evaluation, AstraZeneca Great. The 3rd edition is not only an update. It’s an outstandingly featured summary on the challenges of pharma innovation. Eckard von Keutz, SVP and Head of Early Development, Bayer Healthcare.
Business. --- Pharmacy. --- Management. --- Industrial management. --- Health care management. --- Health services administration. --- Pharmaceutical technology. --- Pharmacy management. --- Health economics. --- Medical economics. --- Business and Management. --- Innovation/Technology Management. --- Pharmaceutical Sciences/Technology. --- Pharmacoeconomics and Health Outcomes. --- Health Care Management. --- Health Economics. --- Pharmaceutical industry --- Technological innovations. --- Medical innovations --- Economics, Medical --- Health --- Health economics --- Hygiene --- Medical care --- Medicine --- Health administration --- Health care administration --- Health care management --- Health sciences administration --- Health services management --- Health planning --- Public health administration --- Chemistry --- Drugs --- Materia medica --- Pharmacology --- Pharmaceutical laboratory techniques --- Pharmaceutical laboratory technology --- Technology, Pharmaceutical --- Technology --- Administration --- Industrial relations --- Organization --- Economic aspects --- Management --- Pharmacy --- Pharmacy administration --- Drugstores --- Health services administration --- Business administration --- Business enterprises --- Business management --- Corporate management --- Corporations --- Industrial administration --- Management, Industrial --- Rationalization of industry --- Scientific management --- Business --- Industrial organization
Choose an application
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation. Health care innovation is possibly the greatest opportunity and challenge of our generation. This important book shows how pharmaceutical companies will continue to play an instrument role in making our lives better. Stefan Thomke, William Barclay Harding Professor of Business Administration, Harvard Business School Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book! Karima Boubekeur, VP Emerging Portfolio and Search & Evaluation, AstraZeneca Great. The 3rd edition is not only an update. It’s an outstandingly featured summary on the challenges of pharma innovation. Eckard von Keutz, SVP and Head of Early Development, Bayer Healthcare.
Economics --- Hygiene. Public health. Protection --- Pharmacology. Therapy --- Organization theory --- Production management --- Business management --- farmacologie --- biogeneesmiddelen --- economie --- gezondheidszorg --- management --- intensieve zorgen --- gezondheidseconomie --- informatietechnologie
Choose an application
This book analyses the relationships among product safety strategy and culture, concurrent engineering, new product development (NPD) processes and product safety performance. Product safety is a matter of enormous economic and societal concern, given the safety risks to consumers and the financial risks to producers. Nevertheless, a thorough conceptual understanding of the effects of NPD policies and practices is still largely missing, as several large-scale trends have made clarifying the role of product safety in its socio-economic context difficult, including: the rise of consumerism and the shift in the balance of power from manufacturers to customers and regulators; the internationalization of value chains and the fragmentation of markets worldwide; and technological change leading to a sophistication of products that rendered average consumers increasingly unaware of risk and potential accidents. This volume sets out to close the gaps among research, practice and policy, with an emphasis on advocating responsible product innovation. Through an in-depth study of the durable juvenile products industry, the authors discover important relationships, for example that top management involvement, safety-first culture and robust NPD processes are paramount in increasing product safety and decreasing product recalls in firms. On the other end of the spectrum, concurrent engineering does not automatically lead to product safety, they found no “magic bullet” through which product safety can be tied to the use of a particular tool, skill, or practice. Offering a dynamic framework for aligning the interests of multiple stakeholders, including manufacturers, regulators, and consumers, the authors provide a clearer understanding of product safety and its implications for scholars, students, policy makers, and practitioners in the areas of innovation management, product management, R&D management, and responsible research and innovation.
Economic policy and planning (general) --- Applied physical engineering --- Organization theory --- Production management --- Business management --- technologiebeleid --- economische politiek --- management --- projectmanagement --- informatietechnologie --- kwaliteitscontrole --- ingenieurswetenschappen
Listing 1 - 4 of 4 |
Sort by
|